The cell therapy market is valued at 15 billion dollars and is set to double in value by 2030. Cell therapy has been instrumental in the development of treatments like CAR-T therapy, which uses the body’s own T cells to fight cancer. The opportunity within cell therapy is significant, targeting common diseases that afflict millions […]
A decade ago, the emergence of new immunotherapies in the cell and gene therapy (CGT) space opened up new avenues to treat disease, sparking excitement across the industry. However, the path to commercialization has been a steep learning curve for both companies and regulatory agencies given the uncharted waters of these new modalities. Now that […]
By 2026, commercial chimeric antigen receptor (CAR)-T cell therapies are on track to make up the largest share of oncology drug sales for pediatric and young adult patients1. This is impressive given that the first CAR-T therapies only gained US Food and Drug Administration (FDA) approval in 2017 and demonstrates the power of these new […]
Cell and gene therapies represent an expanding category of transformative medicines with the potential to change the way we treat human diseases. Broadly, these novel therapies include both in vivo and ex vivo strategies to modify target cells. Ex vivo therapies that involve isolating cells from a patient (autologous) or a donor (allogeneic) and modifying […]
In the past decade, emerging therapeutic modalities like cell and gene therapies have opened up new treatment options for previously intractable diseases, changing the industry needs for primary tissues. While autologous therapies—which are created using a patient’s own cells—still dominate the field, many cell and gene developers are investing in allogeneic therapies that can be […]
Primary cells, such as those isolated from the bone marrow or peripheral blood, are important for a wide scope of research and clinical applications – from studying molecular mechanisms driving disease progression, to developing ex vivo therapies in regenerative medicine. Unlike immortalized cell lines, primary cells have a finite lifespan in culture and can undergo unwanted changes like genetic drift and […]
Adoptive cell therapies (ACTs), which is a treatment based on transferring cells (most often immune cells) into a patient, have revolutionized the standard of care to treat a broad range of diseases. It has perhaps made the most impact in cancer immunotherapy where the successes of chimeric antigen receptor (CAR) T cell therapies to treat […]
Isolated human primary cells are able to retain the morphological and functional characteristics of their tissue of origin, which makes them invaluable tools in life sciences to advance our understanding of cellular biology and molecular mechanisms that are aiding researchers in the development of novel therapeutic approaches to treat human diseases. For instance, primary lymphocytes […]
Expansion of GMP capabilities to support the rapidly growing cell and gene therapy industry AllCells Alameda, CA Expands GMP Processing Capabilities AllCells, the industry leader in the procurement and customization of human-derived hematological tissues and services, is pleased to announce the expansion of its flagship processing facility in Alameda, California. The expansion includes the addition […]
T cells are the main effector cells of the adaptive immune system and can be distinguished from other white blood cells by the presence of a T-cell receptor (TCR) on their cell surface. Differentiated from bone marrow-derived hematopoietic stem cells, T cells migrate from the thymus gland where they mature into CD4+ and CD8+ T […]
